Trial Profile
A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs ASC-09/ritonavir (Primary) ; Interferon; Lopinavir/ritonavir; Umifenovir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 20 Feb 2020 New trial record